表紙
市場調査レポート

世界の医薬品製造、研究開発、パッケージング受託市場:欧州

Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on Europe

発行 BCC Research 商品コード 210426
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
世界の医薬品製造、研究開発、パッケージング受託市場:欧州 Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on Europe
出版日: 2011年09月08日 ページ情報: 英文
概要

欧州のOTC薬、栄養製品のための製造受託市場は2010年に460億米ドル、2011年には513億米ドルとなり、2016年までにCAGR11%の865億米ドルまで成長すると予測されています。一方、欧州の医薬品研究開発受託市場の収益は2009年に58億米ドル、2010年に63億米ドルとなりました。今後もCAGR8.7%で拡大し、2016年には105億米ドル規模となる見通しです。

当レポートでは、世界および欧州の医薬品製造、研究開発、パッケージングの受託市場について調査分析し、サービスの概要、法規制の側面、欧州業界構造、技術移転と新規開発に関する契約、応用分野、および参入企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 定義
  • アウトソーシングの歴史
  • アウトソーシング

第4章 医薬品製造受託概要

  • 製造受託機関の種類
  • 製造受託経路
    • 要件
    • 融通性
    • コストを除く能力
  • 製造受託の長所と短所
  • 製造受託に関する追加的事実
    • 場所と近接性
    • アフターサポート

第5章 医薬品研究開発受託の概要

  • 概要
  • CROが提供するサービス
  • CROの選定
  • CROが提供する研究

第6章 パッケージング受託の概要

  • パッケージング業者の必要性
  • パッケージング業者の選定
  • 受託機関の雇用
  • パッケージングの種類

第7章 プロジェクトマネジメント

  • プロジェクトマネジメントの仕様
  • プロジェクトマネジメントのプロセス
  • 関連因子
  • プロジェクトマネージャーの役割
  • 技術移転

第8章 法規制の側面

  • 法規制の側面
  • 警告文
  • 法規制の承認

第9章 欧州の業界構造

  • 業界リーダーの市場シェア
  • バルク剤とAPIの製造受託機関
  • 固形剤の製造受託機関
  • 液剤の製造受託機関
  • 非滅菌品
  • 滅菌品
  • 半液体材料の製造受託機関
  • 研究受託会社

第10章 技術移転

  • 技術移転の理由
  • 技術移転中の問題
  • 技術移転
  • 成功する技術移転の手続き
  • 技術移転で用いられる契約の種類
    • 機密保持契約
    • 材料移転契約
    • ライセンス契約
    • 共同開発・共同マーケティング契約
  • 成功するプロジェクトの特性

第11章 新規開発

  • LONZA
  • ABBOTT
  • HOSPIRA
  • COVIDIEN
  • その他

第12章 欧州市場分析

  • 製造受託
    • バルク剤/APIの製造受託
    • 経口薬の製造受託
    • 液剤の製造受託
    • 最新ドラッグデリバリー製品
    • OTC・栄養製品
  • 医薬品研究開発受託
  • 医薬品パッケージング受託

第13章 地域別市場シェア

第14章 欧州市場における製造受託の応用分野

  • 心血管
  • 生殖薬剤
  • 鎮痛剤
  • 抗生物質
  • その他

第15章 特許分析

第16章 現在の環境

第17章 企業プロファイル

目次
Product Code: PHM104A

Abstract

REPORT HIGHLIGHTS

  • The global pharmaceutical contract manufacturing and contract research organizations revenue reached at $196.5 billion in 2010, it will further grow to $217.9 billion in 2011 and is projected to reach at $360.6 billion by 2016, increasing at a compound annual growth rate (CAGR) of 10.6%.
  • The European contract manufacturing market for OTC and nutritional products was valued at about $46.0 billion in 2010 and is projected to reach approximately $51.3 in 2011 and it will further grow to $86.5 billion by 2016, at a compound annual growth rate (CAGR) of 11%.
  • The contract research market revenue for Europe in 2009 was $5.8 billion, which reached $6.3 billion in 2010. This market is expected to reach at $6.9 billion in 2011 and it will further grow to $10.5 billion by 2016, at a compound annual growth rate (CAGR) of 8.7%.

image1

Table of Contents

CHAPTER ONE: INTRODUCTION

  • STUDY OBJECTIVE
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

CHAPTER TWO: SUMMARY

  • SUMMARY
  • SUMMARY (CONTINUED)
  • SUMMARY TABLE GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING AND CONTRACT RESEARCH
  • ORGANIZATIONS REVENUE, THROUGH 2016 ($ BILLIONS)
  • SUMMARY FIGURE GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING AND CONTRACT RESEARCH
  • ORGANIZATIONS REVENUE, 2009-2016 ($ BILLIONS)

CHAPTER THREE: OVERVIEW

  • DEFINITIONS
  • DEFINITIONS (CONTINUED)
  • HISTORY OF OUTSOURCING
    • TABLE 1. KEY DEVELOPMENTS IN THE HISTORY OF
  • OUTSOURCING
    • TABLE 1. (CONTINUED)

CHAPTER FOUR: OVERVIEW OF CONTRACT MANUFACTURING

  • TYPES OF CONTRACT MANUFACTURERS
  • CONTRACT MANUFACTURING TRAITS
  • REQUIREMENT
  • ABILITY TO BE FLEXIBLE
  • CAPABILITIES WITHOUT COST
  • ADVANTAGES AND DISADVANTAGES OF CONTRACT MANUFACTURING
    • TABLE 2. KEY ADVANTAGES OF CONTRACT MANUFACTURING
    • TABLE 3. KEY DISADVANTAGES OF CONTRACT MANUFACTURING SELECTING A CONTRACT MANUFACTURER
    • TABLE 4. KEY FACTORS IN SELECTING A CONTRACT MANUFACTURER
    • TABLE 4. (CONTINUED)
  • ADDITIONAL FACTS ABOUT CONTRACT MANUFACTURING
  • LOCATION AND PROXIMITY
  • AFTER-SALES SUPPORT

CHAPTER FIVE: OVERVIEW OF CONTRACT RESEARCH

  • OVERVIEW OF CONTRACT RESEARCH
  • SERVICES OFFERED BY CONTRACT RESEARCH ORGANIZATIONS
    • TABLE 5. SERVICES OF CONTRACT RESEARCH ORGANIZATIONS
    • TABLE 5. (CONTINUED)
  • SELECTING A CONTRACT RESEARCH ORGANIZATION
    • TABLE 6. KEY CHARACTERISITCS IN SELECTING A CONTRACT RESEARCH ORGANIZATION
    • TABLE 6. (CONTINUED)
  • RESEARCH PROVIDED BY CONTRACT RESEARCH ORGNIZATIONS
    • TABLE 7. TYPES OF RESEARCH PROVIDED BY CONTRACT RESEARCH ORGANIZATIONS
    • TABLE 7. (CONTINUED)

CHAPTER SIX: OVERVIEW OF CONTRACT PACKAGING

  • NEEDING A CONTRACT PACKAGER
    • TABLE 8. REASONS BEHIND NEEDING A CONTRACT PACKAGER
    • TABLE 8. (CONTINUED)
  • SELECTING A CONTRACT PACKAGER
    • TABLE 9. KEY CHARACTERISTICS IN SELECTING A CONTRACT PACKAGER
  • HIRING A CONTRACT PACKAGER
    • TABLE 10. KEY STEPS IN HIRING A CONTRACT PACKAGER
  • TYPES OF PACKAGING
  • TYPES OF PACKAGING (CONTINUED)

CHAPTER SEVEN: PROJECT MANAGEMENT

  • SPECIFICATIONS OF PROJECT MANAGEMENT
    • TABLE 11. STEPS OF PROJECT MANAGEMENT
    • TABLE 11. (CONTINUED)
  • PROCESSES OF PROJECT MANAGEMENT
    • TABLE 12. PROCESSES OF PROJECT MANAGEMENT
    • TABLE 12. (CONTINUED)
  • FACTORS INVOLVED
  • ROLE OF THE PROJECT MANAGER
    • TABLE 13. KEY RESPONSIBILITIES OF PROJECT MANAGERS
  • TECHNOLOGY TRANSFER
    • TABLE 14. TECHNOLOGY TRANSFER STEPS

CHAPTER EIGHT: REGULATORY ASPECTS

  • REGULATORY ASPECTS
    • TABLE 15. REGULATED FACTORS OF CMO'S AND CRO'S
    • TABLE 16. TITLE 21 CFR RULES ASSOCIATED WITH CONTRACT MANUFACTURING
    • TABLE 16. (CONTINUED)
    • TABLE 16. (CONTINUED)
  • WARNING LETTERS
    • TABLE 17. WARNING LETTERS ISSUED TO CONTRACT MANUFACTURERS, 2010
    • TABLE 18. WARNING LETTERS ISSUED TO CONTRACT MANUFACTURERS, 2009
  • REGULATORY APPROVALS
    • TABLE 19. REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, JANUARY THROUGH MARCH, 2011
    • TABLE 20. REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2010
    • TABLE 20. (CONTINUED)
    • TABLE 21. REGULATORY APPROVALS OF CONTRACT MANUFACTURERS AND FACILITIES, 2009
    • TABLE 21. (CONTINUED)

CHAPTER NINE: INDUSTRY STRUCTURE FOR EUROPE

  • MARKET SHARE OF INDUSTRY LEADERS
  • CONTRACT MANUFACTURERS OF BULK DRUGS AND API'S
    • TABLE 22. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING BULK DRUGS/API'S, IN EUROPE, 2010 (%)
    • TABLE 22. (CONTINUED)
    • FIGURE 1. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING BULK DRUGS/API'S, IN EUROPE, 2010 (%)
  • CONTRACT MANUFACTURERS OF SOLID DOSAGE FORMS
    • TABLE 23. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SOLID DOSAGE FORMS, IN EUROPE, 2010 (%)
    • FIGURE 2. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SOLID DOSAGE FORMS, IN EUROPE, 2010 (%)
  • CONTRACT MANUFACTURERS OF LIQUID DOSAGE FORMS
  • NONSTERILE
    • TABLE 24. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING NONSTERILE LIQUID DOSAGE FORMS, IN EUROPE, 2010 (%)
    • FIGURE 3. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING NONSTERILE LIQUID DOSAGE FORMS, IN EUROPE, 2010 (%)
  • STERILE
    • TABLE 25. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING STERILE LIQUID DOSAGE FORMS, IN EUROPE, 2010 (%)
    • FIGURE 4. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING STERILE LIQUID DOSAGE FORMS, IN EUROPE, 2010 (%)
  • CONTRACT MANUFACTURING OF SEMISOLID DOSAGE FORMS
    • TABLE 26. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SEMISOLID DOSAGE FORMS, IN EUROPE, 2010 (%)
    • FIGURE 5. MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES PROVIDING SEMISOLID DOSAGE FORMS, IN EUROPE, 2010 (%)
  • CONTRACT RESEARCH COMPANIES
    • TABLE 27. MARKET SHARE OF CONTRACT RESEARCH COMPANIES, IN EUROPE, 2010 (%)
    • FIGURE 6. MARKET SHARE OF CONTRACT RESEARCH COMPANIES, IN EUROPE, 2010 (%)
    • TABLE 28. MARKET SHARE OF CONTRACT PACKAGING COMPANIES, IN EUROPE, 2010 (%)
    • FIGURE 7. MARKET SHARE OF CONTRACT PACKAGING COMPANIES, IN EUROPE, 2010 (%)

CHAPTER TEN: TECHNOLOGY TRANSFER

  • REASONS FOR TECHNOLOGY TRANSFER
  • CHALLENGING PROBLEMS DURING TECHNOLOGY TRANSFER
  • TECHNOLOGY TRANSFER
  • STEPS FOR SUCCESSFUL TECHNOLOGY TRANSFER
  • TYPES OF CONTRACTUAL AGREEMENTS USED IN TECHNOLOGY TRANSFER
  • CONFIDENTIAL DISCLOSURE AGREEMENT (CDA)
  • MATERIAL TRANSFER AGREEMENT (MTA)
  • ASSIGNMENT DEED
  • LICENSE AGREEMENT
  • CO-DEVELOPMENT AND CO-MARKETING AGREEMENTS
  • CHARACTERISTICS OF A SUCCESSFUL PROJECT
  • CHARACTERISTICS OF A SUCCESSFUL ... (CONTINUED)

CHAPTER ELEVEN: NEW DEVELOPMENTS

  • LONZA
  • ABBOTT
  • HOSPIRA
  • COVIDIEN
  • OTHER
  • OTHER (CONTINUED)

CHAPTER TWELVE: MARKET ANALYSIS FOR EUROPE

  • CONTRACT MANUFACTURING
  • CONTRACT MANUFACTURE OF BULK DRUGS/API'S
  • Market Overview
  • Market Revenue
    • TABLE 29. BULK DRUG/API CONTRACT MANUFACTURING REVENUE, FOR EUROPE, THROUGH 2016 ($ BILLIONS)
    • FIGURE 8. BULK DRUG/API CONTRACT MANUFACTURING REVENUE, FOR EUROPE, 2009-2016 ($ BILLIONS)
  • CONTRACT MANUFACTURE OF ORAL DOSAGE FORMULATIONS
  • Solid Dosage Formulations
  • Market Overview
  • Market Revenue
    • TABLE 30. SOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR EUROPE, THROUGH 2016 ($ BILLIONS)
    • FIGURE 9. SOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR EUROPE, 2009- 2016 ($ BILLIONS)
  • Market by Formulation
  • Market Revenue
    • TABLE 31. SOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ BILLIONS)
    • FIGURE 10. SOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BY FORMULATIONS, FOR EUROPE, 2009-2016 ($ BILLIONS)
    • TABLE 32. SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARES, BY FORMULATION, FOR EUROPE, 2010 (%)
    • FIGURE 11. SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARES, BY FORMULATIONS, FOR EUROPE, 2010 (%)
  • Liquid Dosage Formulation
  • Market Overview
  • Market Revenue
  • Nonsterile Formulations
    • TABLE 33. LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING, FOR EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 12. LIQUID DOSAGE FORM (NONSTERILE) CONTRACT
  • MANUFACTURING, FOR EUROPE, 2009-2016 ($ MILLIONS)
  • Sterile Formulations
    • TABLE 34. LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING, FOR EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 13. LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING, FOR EUROPE, 2009-2016 ($ MILLIONS)
  • Market by Formulation
  • Nonsterile Formulations
    • TABLE 35. LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING REVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 14. LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING REVENUE, BY FORMULATIONS, FOR EUROPE, 2009-2016 ($ MILLIONS)
    • TABLE 36. LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING MARKET SHARES, BY FORMULATION, FOR EUROPE, 2010 (%)
    • FIGURE 15. LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING MARKET SHARES, BY FORMULATIONS, FOR EUROPE, 2010 (%)
  • Sterile Formulations
    • TABLE 37. LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING REVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 16. LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING REVENUE, BY FORMULATION, FOR EUROPE, 2009-2016 ($ MILLIONS)
    • TABLE 38. LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING MARKET SHARE, BY FORMULATION, FOR EUROPE, 2010 (%)
    • FIGURE 17. LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING MARKET SHARE, BY FORMULATIONS, FOR EUROPE, 2010 (%)
  • CONTRACT MANUFACTURE OF SEMISOLID DOSAGE FORMULATIONS
  • Market Overview
  • Market Revenue
    • TABLE 39. SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 18. SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR EUROPE, 2009-2016 ($ MILLIONS)
    • TABLE 40. SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 19. SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BY FORMULATIONS, FOR EUROPE, 2009-2016 ($ MILLIONS)
    • TABLE 41. SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARE, BY FORMULATION, FOR EUROPE, 2010 (%)
    • FIGURE 20. SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARE, BY FORMULATIONS, FOR EUROPE, 2010 (%)
  • CONTRACT MANUFACTURE OF ADVANCED DRUG DELIVERY PRODUCTS
  • Market Overview
    • TABLE 42. CONTRACTING COMPANIES PROVIDING DRUG DELIVERY SYSTEMS
  • Market Revenue
    • TABLE 43. ADVANCED DRUG DELIVERY SYSTEMS REVENUE, BY CONTRACT MANUFACTURING, FOR EUROPE, THROUGH 2016 ($BILLIONS)
    • FIGURE 21. ADVANCED DRUG DELIVERY SYSTEMS REVENUE, BY CONTRACT MANUFACTURING, FOR EUROPE, 2009-2016 ($BILLIONS)
  • Market by Formulation
    • TABLE 44. ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURING REVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 22. ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURING REVENUE, BY FORMULATIONS, FOR EUROPE, 2009-2016 ($ MILLIONS)
  • Market Share
    • TABLE 45. ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURING MARKET SHARE, BY FORMULATION, FOR EUROPE, 2010 (%)
    • FIGURE 23. ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURING MARKET SHARE, BY FORMULATIONS, FOR EUROPE, 2010 (%)
  • CONTRACT MANUFACTURE OF OTC AND NUTRITIONAL PRODUCTS
  • Market Revenue
    • TABLE 46. OTC AND NUTRITIONAL PRODUCTS REVENUE, BY CONTRACT MANUFACTURING, FOR EUROPE, THROUGH 2016 ($ BILLIONS)
    • FIGURE 24. OTC AND NUTRITIONAL PRODUCTS REVENUE, BY CONTRACT MANUFACTURING, FOR EUROPE, 2009-2016 ($ BILLIONS)
  • Market by Formulation
    • TABLE 47. OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURING REVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ BILLIONS)
    • FIGURE 25. OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURING REVENUE, BY FORMULATIONS, FOR EUROPE, 2009-2016 ($ BILLIONS)
  • Market Shares
    • TABLE 48. OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURING MARKET SHARE, BY FORMULATION, FOR EUROPE, 2010 (%)
    • FIGURE 26. OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURING MARKET SHARE, BY FORMULATIONS, FOR EUROPE, 2010 (%)
  • CONTRACT RESEARCH
  • MARKET OVERVIEW
  • Partnerships
  • Expansions of Facilities
  • Market Revenue
    • TABLE 49. CONTRACT RESEARCH REVENUE, FOR EUROPE, THROUGH 2016 ($ BILLIONS)
    • FIGURE 27. CONTRACT RESEARCH REVENUE, FOR EUROPE, 2009-2016 ($ BILLIONS)
  • Market by Discipline
    • TABLE 50. CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 28. CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR EUROPE, 2009-2016 ($ MILLIONS)
  • Market Share by Discipline
    • TABLE 51. CONTRACT RESEARCH MARKET SHARE, BY DISCIPLINE, FOR EUROPE, 2010 (%)
    • FIGURE 29. CONTRACT RESEARCH MARKET SHARE, BY DISCIPLINE, FOR EUROPE, 2010 (%)
  • CONTRACT PACKAGING
  • MARKET OVERVIEW
  • Market Revenue
    • TABLE 52. CONTRACT PACKAGING REVENUE, FOR EUROPE, THROUGH 2016 ($ BILLIONS)
    • FIGURE 30. CONTRACT PACKAGING REVENUE, FOR EUROPE, 2009-2016 ($ BILLIONS)
  • Market by Package Type
    • TABLE 53. CONTRACT PACKAGING REVENUE BY TYPE, FOR EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 31. CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR EUROPE, 2009-2016 ($ BILLIONS)
  • Market Share by Type
    • TABLE 54. CONTRACT PACKAGING MARKET SHARE BY TYPE, FOR EUROPE, 2010 (%)
    • FIGURE 32. CONTRACT PACKAGING MARKET SHARE BY TYPE, FOR EUROPE, 2010 (%)

CHAPTER THIRTEEN: MARKET SHARE BY REGION

  • MARKET SHARE OF CONTRACT MANUFACTURED API'S
    • TABLE 55. BULK DRUG/API CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
    • FIGURE 33. BULK DRUG/API CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
  • MARKET SHARE OF CONTRACT MANUFACTURED SOLID DOSAGE FORMS
    • TABLE 56. SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
    • FIGURE 34. SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
  • MARKET SHARE OF CONTRACT MANUFACTURED LIQUID DOSAGE FORMULATIONS
  • NONSTERILE FORMULATIONS
    • TABLE 57. LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
    • FIGURE 35. LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
  • STERILE FORMULATIONS
    • TABLE 58. LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
    • FIGURE 36. LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
  • MARKET SHARE OF CONTRACT MANUFACTURED SEMISOLID DOSAGE FORMULATIONS
    • TABLE 59. SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARES, BY REGION, 2010 (%)
    • FIGURE 37. SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
  • MARKET SHARE OF CONTRACT MANUFACTURED ADVANCED DRUG DELIVERY PRODUCTS
    • TABLE 60. DRUG DELIVERY CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
    • FIGURE 38. DRUG DELIVERY CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
  • MARKET SHARE OF CONTRACT MANUFACTURED OTC AND NUTRITIONAL PRODUCTS
    • TABLE 61. OTC AND NUTRITIONAL PRODUCTS CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
    • FIGURE 39. OTC AND NUTRITIONAL PRODUCT CONTRACT MANUFACTURING MARKET SHARE, BY REGION, 2010 (%)
  • MARKET SHARE OF CONTRACT RESEARCH
    • TABLE 62. CONTRACT RESEARCH MARKET SHARE, BY REGION, 2010 (%)
    • FIGURE 40. CONTRACT RESEARCH MARKET SHARE, BY REGION, 2010 (%)
  • MARKET SHARE OF CONTRACT PACKAGING
    • TABLE 63. CONTRACT PACKAGING MARKET SHARE, BY REGION, 2010 (%)
    • FIGURE 41. CONTRACT PACKAGING MARKET SHARE, BY REGION, 2010 (%)

CHAPTER FOURTEEN: CONTRACT MANUFACTURING APPLICATIONS FOR EUROPEAN MARKETS

  • CARDIOVASCULAR DRUGS
  • MARKET REVENUE
    • TABLE 64. REVENUE FROM CONTRACT MANUFACTURERS OF CARDIOVASCULAR DRUGS, IN EUROPE, THROUGH 2016 ($MILLIONS)
    • FIGURE 42. REVENUE FROM CONTRACT MANUFACTURERS OF CARDIOVASCULAR DRUGS, IN EUROPE, 2009-2016 ($ MILLIONS)
  • REPRODUCTIVE DRUG MARKET
  • MARKET REVENUE
    • TABLE 65. REVENUE FROM CONTRACT MANUFACTURERS OF REPRODUCTIVE DRUGS, IN EUROPE, THROUGH 2016 ($MILLIONS)
    • FIGURE 43. REVENUE FROM CONTRACT MANUFACTURERS OF REPRODUCTIVE DRUGS, IN EUROPE, 2009-2016 ($ MILLIONS)
  • ONCOLOGY DRUG MARKET
  • MARKET REVENUE
    • TABLE 66. REVENUE FROM CONTRACT MANUFACTURERS OF ONCOLOGY DRUGS, IN EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 44. REVENUE FROM CONTRACT MANUFACTURERS OF ONCOLOGY DRUGS, IN EUROPE, 2009-2016 ($ MILLIONS)
  • ANALGESICS MARKET
  • MARKET REVENUE
    • TABLE 67. REVENUE FROM CONTRACT MANUFACTURERS OF ANALGESICS, IN EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 45. REVENUE FROM CONTRACT MANUFACTURERS OF ANALGESICS, IN EUROPE, 2009-2016 ($ MILLIONS)
  • ANTIVIRAL DRUG MARKET
  • MARKET REVENUE
    • TABLE 68. REVENUE FROM CONTRACT MANUFACTURERS OF ANTIVIRALS, IN EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 46. REVENUE FROM CONTRACT MANUFACTURERS OF ANTIVIRALS, IN EUROPE, 2009-2016 ($ MILLIONS)
  • ANTIBIOTICS MARKET
  • MARKET REVENUE
    • TABLE 69. REVENUE FROM CONTRACT MANUFACTURERS OF ANTIBIOTICS, IN EUROPE, THROUGH 2016 ($ MILLIONS)
    • FIGURE 47. REVENUE FROM CONTRACT MANUFACTURERS OF ANTIBIOTICS, IN EUROPE, 2009-2016 ($ MILLIONS)
  • MARKETS FOR OTHER DRUGS
  • MARKET REVENUE
    • TABLE 70. REVENUE FROM CONTRACT MANUFACTURERS OF OTHER DRUGS, IN EUROPE, THROUGH 2016 ($ BILLIONS)
    • FIGURE 48. REVENUE FROM CONTRACT MANUFACTURERS OF OTHER DRUGS, IN EUROPE, 2009-2016 ($ BILLIONS)

CHAPTER FIFTEEN: PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 71. NUMBER OF SIGNIFICANT PATENTS, BY YEAR, 2009-2011
    • FIGURE 49. NUMBER OF PATENTS, BY YEAR, 2009-MAY 31, 2011
    • FIGURE 50. NUMBER OF PATENTS, BY YEAR, 2009-MAY 31, 2011 (%) PATENTS BY COMPANY
    • TABLE 72. NUMBER OF U.S. PATENTS, BY COMPANY, 2009-2011
    • FIGURE 51. NUMBER OF U.S. PATENTS, BY COMPANY, 2009-2011
  • PATENTS BY COUNTRY
    • TABLE 73. NUMBER OF U.S. PATENTS, BY COUNTRY, 1/1/2009 TO 5/31/2011
    • FIGURE 52. NUMBER OF U.S. PATENTS, BY COUNTRY, 1/1/2009 TO 5/31/2011
    • TABLE 74. PATENT SHARES, BY COUNTRY, 1/1/2009 TO 5/31/2011 (%)
    • FIGURE 53. PATENT SHARES, BY COUNTRY, 1/1/2009 TO 5/31/2011 (%)
  • PATENTS BY EMPHASIS
    • TABLE 75. PATENTS, BY EMPHASIS, 1/1/2009 TO 5/31/2011
    • FIGURE 54. NUMBER OF U.S. PATENTS, BY EMPHASIS, 1/1/2009 TO 5/31/2011

CHAPTER SIXTEEN: CURRENT ENVIRONMENT

  • SITUATION OF THE NORTH AMERICAN CONTRACTING MARKETS
  • CONTRACT MANUFACTURING OF API AND DOSAGE FORMS
  • CONTRACT MANUFACTURING OF OTC AND NUTRACEUTICALS
  • CONTRACT RESEARCH
  • CONTRACT PACKAGING
  • SITUATION OF THE EUROPEAN CONTRACTING MARKET
  • CONTRACT MANUFACTURING OF API AND DOSAGE FORMS
  • CONTRACT MANUFACTURING OF OTC AND NUTRACEUTICALS
  • CONTRACT RESEARCH
  • CONTRACT PACKAGING
  • SITUATION OF THE ROW CONTRACTING MARKET
  • CONTRACT MANUFACTURING OF API AND DOSAGE FORMS
  • CONTRACT MANUFACTURING OF OTC AND NUTRACEUTICALS
  • CONTRACT RESEARCH
  • CONTRACT PACKAGING
  • OPPORTUNITIES AND CHALLENGES OF THE CURRENT CONTRACT MANUFACTURING INDUSTRY
  • OPPORTUNITIES AND CHALLENGES...(CONTINUED)
  • OPPORTUNITIES AND CHALLENGES...(CONTINUED)

CHAPTER SEVENTEEN: COMPANY PROFILES

  • AAI PHARMA, INC.
  • ABBOTT LABORATORIES
  • AEROGEN LTD.
  • ALKERMES
  • ALTHEA TECHNOLOGIES
  • AMCOR
  • AMERISOURCE BERGEN CORPORATION
  • AMPAC FINE CHEMICALS
  • ALBANY MOLECULAR RESEARCH INC. (AMRI)
  • AP PHARMA INC.
  • APTUIT INC.
  • ARADIGM CORPORATION
  • BASF SE
  • BAXTER HEALTHCARE
  • BCM/BOOTS MANUFACTURING
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB
  • CAMBREX CORPORATION
  • CANGENE CORPORATION
  • CATALENT PHARMA SOLUTIONS
  • CEDARBURG HAUSER PHARMACEUTICALS INC.
  • CENEXI
  • CHARLES RIVER LABORATORIES
  • CHEMBRIDGE CORP.
  • CLEARSTONE CENTRAL LABORATORIES
  • CONFAB LABORATORIES
  • COVANCE INC.
  • COVIDIEN
  • CONTRACT PHARMACEUTICALS LIMITED
  • CORDEN PHARMA SWITZERLAND LLC
  • DAVOS PHARMA
  • DECODE GENETICS
  • DISHMAN PHARMACEUTICALS AND CHEMICALS LTD.
  • DOW CHEMICAL
  • DPT LABORATORIES INC.
  • DR. REDDY'S LABORATORIES
  • DSM PHARMACEUTICAL PRODUCTS
  • FUJIFILM DIOSYNTH BIOTECHNOLOGY
  • ELAN DRUG TECHNOLOGIES
  • EVOTEC AG
  • FULCRUM PHARMA PLC
  • GIRINDUS AG
  • GLAXOSMITHKLINE
  • HOSPIRA
  • HAUPT PHARMA AG
  • HOVIONE S.A
  • ICON PLC
  • INC RESEARCH, INC.
  • JUBILANT LIFESCIENCES
  • KENDLE INTERNATIONAL INC.
  • KP PHARMACEUTICAL TECHNOLOGIES INC.
  • K.V. PHARMACEUTICAL CO.
  • LIGAND PHARMACEUTICALS, INC.
  • LONZA GROUP
  • LYNE LABORATORIES
  • MERCK / MSD BIOMANUFACTURING NETWORK
  • MIKART INC
  • NEXTPHARMA TECHNOLOGIES
  • NORWICH PHARMACEUTICALS
  • NOVAVAX, INC.
  • OMNICARE CLINICAL RESEARCH
  • PAREXEL INTERNATIONAL CORPORATION
  • PATHEON INC.
  • PERRIGO COMPANY
  • PFIZER (KING PHARMACEUTICALS
  • PIRAMAL HEALTHCARE LIMITED
  • PPD
  • PRA INTERNATIONAL
  • QUINTILES
  • RANBAXY
  • REGIS TECHNOLOGIES, INC.
  • SKYEPHARMA
  • TALECRIS BIOTHERAPEUTICS INC.
  • VETTER PHARMA INTERNATIONAL GMBH WOCKHARDT LIMITED
  • WUXI APP TEC
  • XCELLEREX LLC
  • ZACH SYSTEM S.P.A
  • APPENDIX I: ABBREVIATIONS
Back to Top